Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
443 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01241591 | A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis | completed | Phase 3 | 1,101 | PfizerINDUSTRY | 26 | Dec 26, 2018 | clinicaltrials |
| NCT00974311 | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy(AFFIRM) | completed | Phase 3 | 1,199 | PfizerINDUSTRY | 15 |
| Dec 11, 2018 |
| clinicaltrials |
| NCT00002565 | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | completed | Phase 3 | 61 | M.D. Anderson Cancer CenterOTHER | 3 | Nov 14, 2018 | clinicaltrials |
| NCT00552058 | Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | completed | Phase 3 | 439 | UCB PharmaINDUSTRY | 20 | Aug 9, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT01571284 | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | completed | Phase 3 | 781 | SanofiINDUSTRY | 23 | Apr 17, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT00338286 | A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy | completed | Phase 3 | 2,098 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 19, 2018 | clinicaltrials |
| NCT01032512 | Clinical Benefits of Preoperative Nutrition Support With Enteral Immune-enhancing Formulas in Surgical Oncology | withdrawn | Phase 3 | 0 | University of ChileOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02119663 | A Study of Ruxolitinib in Pancreatic Cancer Patients | terminated | Phase 3 | 86 | Incyte CorporationINDUSTRY | 14 | Feb 13, 2018 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT01646021 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | completed | Phase 3 | 280 | Janssen Research & Development, LLCINDUSTRY | 21 | Jan 19, 2018 | clinicaltrials |
| NCT00036647 | OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 731 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
| NCT00040183 | OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. | completed | Phase 3 | 569 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
| NCT01345669 | LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | terminated | Phase 3 | 617 | Boehringer IngelheimINDUSTRY | 29 | Dec 7, 2017 | clinicaltrials |
| NCT01154140 | A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung(PROFILE 1014) | completed | Phase 3 | 343 | PfizerINDUSTRY | 31 | Nov 6, 2017 | clinicaltrials |
| NCT01516736 | Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim(PROTECT2) | completed | Phase 3 | 308 | SandozINDUSTRY | 8 | Aug 30, 2017 | clinicaltrials |
| NCT00099177 | A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain | terminated | Phase 3 | 96 | Hoffmann-La RocheINDUSTRY | 16 | Aug 16, 2017 | clinicaltrials |
| NCT00099203 | A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease | terminated | Phase 3 | 163 | Hoffmann-La RocheINDUSTRY | 18 | Aug 16, 2017 | clinicaltrials |
| NCT01163253 | A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis | terminated | Phase 3 | 2,867 | PfizerINDUSTRY | 36 | Jun 26, 2017 | clinicaltrials |
| NCT00294658 | Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy | completed | Phase 3 | 126 | University of Alabama at BirminghamOTHER | 18 | May 23, 2017 | clinicaltrials |
| NCT00428090 | Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease | completed | Phase 3 | 862 | GlaxoSmithKlineINDUSTRY | 20 | May 19, 2017 | clinicaltrials |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,560 | Millennium Pharmaceuticals, Inc.INDUSTRY | 40 | May 17, 2017 | clinicaltrials |
| NCT00045032 | Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer(HERA) | completed | Phase 3 | 5,099 | Hoffmann-La RocheINDUSTRY | 33 | Apr 27, 2017 | clinicaltrials |
| NCT01308580 | Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer(PROSELICA) | completed | Phase 3 | 1,200 | SanofiINDUSTRY | 22 | Apr 17, 2017 | clinicaltrials |
| NCT01412957 | Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 377 | AmgenINDUSTRY | 16 | Mar 15, 2017 | clinicaltrials |
| NCT00481247 | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(DASISION) | completed | Phase 3 | 547 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 15, 2017 | clinicaltrials |
| NCT00806819 | Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC | completed | Phase 3 | 718 | Boehringer IngelheimINDUSTRY | 32 | Feb 2, 2017 | clinicaltrials |
| NCT00154102 | Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)(CRYSTAL) | completed | Phase 3 | 1,221 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 30 | Jan 30, 2017 | clinicaltrials |
| NCT01450696 | A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer(HELOISE) | terminated | Phase 3 | 296 | Hoffmann-La RocheINDUSTRY | 25 | Nov 28, 2016 | clinicaltrials |
| NCT00861614 | Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 988 | Bristol-Myers SquibbINDUSTRY | 27 | Sep 30, 2016 | clinicaltrials |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk(REDUCE) | completed | Phase 3 | 8,231 | GlaxoSmithKlineINDUSTRY | 42 | Sep 23, 2016 | clinicaltrials |
| NCT00022516 | Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer(22-00) | completed | Phase 3 | 1,086 | ETOP IBCSG Partners FoundationNETWORK | 11 | Sep 16, 2016 | clinicaltrials |
| NCT01057810 | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 837 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 18, 2016 | clinicaltrials |
| NCT00519285 | Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer(VENICE) | completed | Phase 3 | 1,224 | SanofiINDUSTRY | 31 | Jul 22, 2016 | clinicaltrials |
| NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer(VANILLA) | terminated | Phase 3 | 546 | SanofiINDUSTRY | 24 | Jun 7, 2016 | clinicaltrials |
| NCT00417209 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen(PAPRIKA) | completed | Phase 3 | 408 | SanofiINDUSTRY | 21 | Jun 3, 2016 | clinicaltrials |
| NCT00174837 | TRACE: Tirapazamine-Radiation And Cisplatin Evaluation(TRACE) | completed | Phase 3 | 317 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT00625664 | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer(CILAB) | completed | Phase 3 | 337 | SanofiINDUSTRY | 19 | May 5, 2016 | clinicaltrials |
| NCT00305188 | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. | completed | Phase 3 | 879 | SanofiINDUSTRY | 13 | May 4, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT01234311 | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 1,245 | Active Biotech ABINDUSTRY | 37 | Oct 21, 2015 | clinicaltrials |
| NCT00075270 | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | completed | Phase 3 | 580 | GlaxoSmithKlineINDUSTRY | 25 | May 6, 2015 | clinicaltrials |
| NCT00117598 | Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)(OPTIMAL) | completed | Phase 3 | 169 | PfizerINDUSTRY | 18 | Mar 30, 2015 | clinicaltrials |
| NCT00457691 | Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 768 | PfizerINDUSTRY | 34 | Mar 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials